세계의 마이크로바이옴 치료 시장

Global Microbiome Therapeutics Market to Reach $19.1 Billion by 2030

The global market for Microbiome Therapeutics estimated at US$820 Million in the year 2023, is expected to reach US$19.1 Billion by 2030, growing at a CAGR of 56.8% over the analysis period 2023-2030. Microbiome Therapeutics for C. Difficile Infection, one of the segments analyzed in the report, is expected to record a 53.2% CAGR and reach US$6.6 Billion by the end of the analysis period. Growth in the Microbiome Therapeutics for Obesity segment is estimated at 56.7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $281.3 Million, While China is Forecast to Grow at 53.4% CAGR

The Microbiome Therapeutics market in the U.S. is estimated at US$281.3 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 53.4% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 49.6% and 47.4% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 37.5% CAGR.

Introducing Our Exciting New Report Features for 2024

Full access to influencer engagement stats

Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.

Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities

Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas

Complimentary report updates for one year

Competitor coverage with global market shares of major players

Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies

Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024

Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 46 Featured) -

• 4D pharma plc
• AOBiome
• Enterome SA
• Evelo Biosciences, Inc.
• Ferring International
• Immuron Ltd.
• LNC Therapeutics
• Microbiome Therapeutics, LLC.
• Osel, Inc.
• OxThera AB
• Rebiotix, Inc.
• Ritter Pharmaceuticals, Inc.
• Second Genome
• Seres Therapeutics, Inc.
• Vedanta Biosciences, Inc.
• ViThera Pharmaceuticals, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Microbiome Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Global Economic Update
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Microbiome Therapeutics Market Analysis of Annual Sales in US$ for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Microbiome Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 3: World 7-Year Perspective for Microbiome Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for C. Difficile Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 5: World 7-Year Perspective for C. Difficile Infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Obesity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 7: World 7-Year Perspective for Obesity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Primary Hyperoxyurea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 9: World 7-Year Perspective for Primary Hyperoxyurea by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Type 2 Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 11: World 7-Year Perspective for Type 2 Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Microbiome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 12: USA Recent Past, Current & Future Analysis for Microbiome Therapeutics by Indication - C. Difficile Infection, Obesity, Primary Hyperoxyurea and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 13: USA 7-Year Perspective for Microbiome Therapeutics by Indication - Percentage Breakdown of Value Sales for C. Difficile Infection, Obesity, Primary Hyperoxyurea and Type 2 Diabetes for the Years 2024 & 2030
• CANADA
  • TABLE 14: Canada Recent Past, Current & Future Analysis for Microbiome Therapeutics by Indication - C. Difficile Infection, Obesity, Primary Hyperoxyurea and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 15: Canada 7-Year Perspective for Microbiome Therapeutics by Indication - Percentage Breakdown of Value Sales for C. Difficile Infection, Obesity, Primary Hyperoxyurea and Type 2 Diabetes for the Years 2024 & 2030
• JAPAN
  • Microbiome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 16: Japan Recent Past, Current & Future Analysis for Microbiome Therapeutics by Indication - C. Difficile Infection, Obesity, Primary Hyperoxyurea and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 17: Japan 7-Year Perspective for Microbiome Therapeutics by Indication - Percentage Breakdown of Value Sales for C. Difficile Infection, Obesity, Primary Hyperoxyurea and Type 2 Diabetes for the Years 2024 & 2030
• CHINA
  • Microbiome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 18: China Recent Past, Current & Future Analysis for Microbiome Therapeutics by Indication - C. Difficile Infection, Obesity, Primary Hyperoxyurea and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 19: China 7-Year Perspective for Microbiome Therapeutics by Indication - Percentage Breakdown of Value Sales for C. Difficile Infection, Obesity, Primary Hyperoxyurea and Type 2 Diabetes for the Years 2024 & 2030
• EUROPE
  • Microbiome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 20: Europe Recent Past, Current & Future Analysis for Microbiome Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 21: Europe 7-Year Perspective for Microbiome Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
  • TABLE 22: Europe Recent Past, Current & Future Analysis for Microbiome Therapeutics by Indication - C. Difficile Infection, Obesity, Primary Hyperoxyurea and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 23: Europe 7-Year Perspective for Microbiome Therapeutics by Indication - Percentage Breakdown of Value Sales for C. Difficile Infection, Obesity, Primary Hyperoxyurea and Type 2 Diabetes for the Years 2024 & 2030
• FRANCE
  • Microbiome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 24: France Recent Past, Current & Future Analysis for Microbiome Therapeutics by Indication - C. Difficile Infection, Obesity, Primary Hyperoxyurea and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 25: France 7-Year Perspective for Microbiome Therapeutics by Indication - Percentage Breakdown of Value Sales for C. Difficile Infection, Obesity, Primary Hyperoxyurea and Type 2 Diabetes for the Years 2024 & 2030
• GERMANY
  • Microbiome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 26: Germany Recent Past, Current & Future Analysis for Microbiome Therapeutics by Indication - C. Difficile Infection, Obesity, Primary Hyperoxyurea and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 27: Germany 7-Year Perspective for Microbiome Therapeutics by Indication - Percentage Breakdown of Value Sales for C. Difficile Infection, Obesity, Primary Hyperoxyurea and Type 2 Diabetes for the Years 2024 & 2030
• ITALY
  • TABLE 28: Italy Recent Past, Current & Future Analysis for Microbiome Therapeutics by Indication - C. Difficile Infection, Obesity, Primary Hyperoxyurea and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 29: Italy 7-Year Perspective for Microbiome Therapeutics by Indication - Percentage Breakdown of Value Sales for C. Difficile Infection, Obesity, Primary Hyperoxyurea and Type 2 Diabetes for the Years 2024 & 2030
• UNITED KINGDOM
  • Microbiome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 30: UK Recent Past, Current & Future Analysis for Microbiome Therapeutics by Indication - C. Difficile Infection, Obesity, Primary Hyperoxyurea and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 31: UK 7-Year Perspective for Microbiome Therapeutics by Indication - Percentage Breakdown of Value Sales for C. Difficile Infection, Obesity, Primary Hyperoxyurea and Type 2 Diabetes for the Years 2024 & 2030
• REST OF EUROPE
  • TABLE 32: Rest of Europe Recent Past, Current & Future Analysis for Microbiome Therapeutics by Indication - C. Difficile Infection, Obesity, Primary Hyperoxyurea and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Rest of Europe 7-Year Perspective for Microbiome Therapeutics by Indication - Percentage Breakdown of Value Sales for C. Difficile Infection, Obesity, Primary Hyperoxyurea and Type 2 Diabetes for the Years 2024 & 2030
• ASIA-PACIFIC
  • Microbiome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 34: Asia-Pacific Recent Past, Current & Future Analysis for Microbiome Therapeutics by Indication - C. Difficile Infection, Obesity, Primary Hyperoxyurea and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 35: Asia-Pacific 7-Year Perspective for Microbiome Therapeutics by Indication - Percentage Breakdown of Value Sales for C. Difficile Infection, Obesity, Primary Hyperoxyurea and Type 2 Diabetes for the Years 2024 & 2030
• REST OF WORLD
  • TABLE 36: Rest of World Recent Past, Current & Future Analysis for Microbiome Therapeutics by Indication - C. Difficile Infection, Obesity, Primary Hyperoxyurea and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 37: Rest of World 7-Year Perspective for Microbiome Therapeutics by Indication - Percentage Breakdown of Value Sales for C. Difficile Infection, Obesity, Primary Hyperoxyurea and Type 2 Diabetes for the Years 2024 & 2030

IV. COMPETITION